Last updated on December 2017

A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Migraine
  • Age: Between 18 - 60 Years
  • Gender: Male or Female

Adults ≥ 18 to ≤ 60 years of age with history of migraine (with or without aura) for ≥ 12 months before screening and who experience ≥ 4 migraine days per month

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.